
Amlodipine (5mg) + Hydrochlorothiazide (12.5mg) + Olmesartan Medoxomil (40mg)
Active composition
+2 more active ingredients
Amlodipine inhibits calcium ion influx into vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial oxygen demand.
Hydrochlorothiazide inhibits sodium reabsorption in the distal convoluted tubule, leading to increased urine output and decreased blood volume.
Olmesartan Medoxomil blocks angiotensin II receptors, preventing vasoconstriction and lowering blood pressure.
Medical applications
Olmewon Plus 40 Tablet is a combination antihypertensive medication containing Olmesartan Medoxomil 40 mg, Amlodipine 5 mg, and Hydrochlorothiazide 12.5 mg. This formulation is designed to provide effective management of hypertension by utilizing three complementary mechanisms of action. Olmesartan Medoxomil, an angiotensin II receptor blocker (ARB), inhibits the vasoconstrictive effects of angiotensin II, thereby reducing peripheral vascular resistance and lowering blood pressure. Amlodipine, a calcium channel blocker, promotes vasodilation by inhibiting calcium ion influx into vascular smooth muscle and cardiac muscle, further aiding in blood pressure reduction and improving myocardial oxygen delivery. Hydrochlorothiazide, a thiazide diuretic, enhances sodium and water excretion by inhibiting sodium reabsorption in the distal convoluted tubules of the kidneys, contributing to decreased blood volume and pressure. The combined action of these agents provides a synergistic effect, improving blood pressure control in patients who may not achieve target levels with monotherapy or dual therapy. Olmewon Plus 40 is indicated for the treatment of essential hypertension and may reduce the risk of cardiovascular events associated with elevated blood pressure. It should be used under medical supervision with appropriate monitoring of renal function, electrolytes, and blood pressure.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Olmewon Plus 40 Tablet is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
High Risk
Olmewon Plus 40 Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Medical Advice
Olmewon Plus 40 Tablet should be used with caution in patients with severe kidney disease. Dose adjustment of Olmewon Plus 40 Tablet may be needed. Please consult your doctor. Use of Olmewon Plus 40 Tablet is not recommended in patients with severe kidney disease.
Exercise Caution
Olmewon Plus 40 Tablet may cause side effects which could affect your ability to drive. Olmewon Plus 40 Tablet may cause side effects such as dizziness, headaches, nausea or tiredness, all of which could affect your ability to concentrate and drive.
Consult Doctor
Olmewon Plus 40 Tablet should be used with caution in patients with liver disease. Dose adjustment of Olmewon Plus 40 Tablet may be needed. Please consult your doctor.
Regular Checkup
0 reviews for Olmewon Plus 40 Tablet

Olmesartan Medoxomil (40mg) + Amlodipine (5mg) + Hydrochlorothiazide (12.5mg)
Cheaper alternative availability
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
Active composition
+2 more active ingredients
Amlodipine inhibits calcium ion influx into vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial oxygen demand.
Hydrochlorothiazide inhibits sodium reabsorption in the distal convoluted tubule, leading to increased urine output and decreased blood volume.
Olmesartan Medoxomil blocks angiotensin II receptors, preventing vasoconstriction and lowering blood pressure.
Medical applications
Olmewon Plus 40 Tablet is a combination antihypertensive medication containing Olmesartan Medoxomil 40 mg, Amlodipine 5 mg, and Hydrochlorothiazide 12.5 mg. This formulation is designed to provide effective management of hypertension by utilizing three complementary mechanisms of action. Olmesartan Medoxomil, an angiotensin II receptor blocker (ARB), inhibits the vasoconstrictive effects of angiotensin II, thereby reducing peripheral vascular resistance and lowering blood pressure. Amlodipine, a calcium channel blocker, promotes vasodilation by inhibiting calcium ion influx into vascular smooth muscle and cardiac muscle, further aiding in blood pressure reduction and improving myocardial oxygen delivery. Hydrochlorothiazide, a thiazide diuretic, enhances sodium and water excretion by inhibiting sodium reabsorption in the distal convoluted tubules of the kidneys, contributing to decreased blood volume and pressure. The combined action of these agents provides a synergistic effect, improving blood pressure control in patients who may not achieve target levels with monotherapy or dual therapy. Olmewon Plus 40 is indicated for the treatment of essential hypertension and may reduce the risk of cardiovascular events associated with elevated blood pressure. It should be used under medical supervision with appropriate monitoring of renal function, electrolytes, and blood pressure.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Olmewon Plus 40 Tablet is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
High Risk
Olmewon Plus 40 Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Medical Advice
Olmewon Plus 40 Tablet should be used with caution in patients with severe kidney disease. Dose adjustment of Olmewon Plus 40 Tablet may be needed. Please consult your doctor. Use of Olmewon Plus 40 Tablet is not recommended in patients with severe kidney disease.
Exercise Caution
Olmewon Plus 40 Tablet may cause side effects which could affect your ability to drive. Olmewon Plus 40 Tablet may cause side effects such as dizziness, headaches, nausea or tiredness, all of which could affect your ability to concentrate and drive.
Consult Doctor
Olmewon Plus 40 Tablet should be used with caution in patients with liver disease. Dose adjustment of Olmewon Plus 40 Tablet may be needed. Please consult your doctor.
Regular Checkup
0 reviews for Olmewon Plus 40 Tablet















